Quanterix to acquire Akoya Biosciences.

Quanterix, a company fueling scientific discovery through ultra-sensitive biomarker detection, agreed to acquire Akoya Biosciences, a biotechnology company in Marlborough, Massachusetts. Under the terms of the agreement, which was approved by the Boards of Directors of both companies, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock owned. “Liquid biopsy will eventually surpass the market size of all other diagnostics testing combined. Enabling early disease detection, before symptoms appear, using non-invasive methods is our mission and will be the majority of Quanterix's long-term value," Masoud Toloue, Quanterix CEO.